Please login to the form below
immunotherapies
This page shows the latest immunotherapies news and features for those working in and with pharma, biotech and healthcare.
Immutep spikes on trial of its LAG-3 drug with Keytruda
Impressive mid-stage results in NSCLC and HNSCC. Shares in Australian biotech Immutep rose quickly on data for its cancer immunotherapy drug eftilagimod alpha alongside Merck &Co’s Keytruda in solid ... for the drug as a standalone immunotherapy.
Latest news
-
GSK pays $50m upfront to tap Immatics’ cell therapy platform
Deal focuses on T cell receptor therapies
-
Merck KGaA divests allergy business to Dermapharm
The Allergopharma business is focused on allergen-specific immunotherapy of type 1 allergies, such as hay fever or allergic asthma.
-
Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC
Solidifies immunotherapy drug's dominance in the setting. Roche has scored approval from China’s National Medical Products Administration for its PD-L1 inhibitor Tecentriq in small cell lung cancer, solidifying ... This approval makes Tecentriq the
-
AZ revenues rise, but it says coronavirus could hit 2020
Oncology sales grew 29% to $2.3bn in the fourth quarter, with its trifecta of cancer immunotherapy Imfinzi (durvalumab), targeted therapy Tagrisso for lung cancer and PARP inhibitor Lynparza (olaparib) for
-
Revenue growth at Ipsen numbs pain of palovarotene calamity
The company is waiting for phase 3 results for Cabometyx in combination with Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in first-line renal cell carcinoma, which could add further momentum
More from news
Approximately 94 fully matching, plus 484 partially matching documents found.
Latest Intelligence
-
It started with a miss
However, we’re now moving into areas like immunotherapy and are on the edge of amazing innovations that will deliver great outcomes for patients.
-
A snapshot of Microbiotica
An area of high interest is the discovery that responses to cancer immunotherapy are dependent on gut bacteria.
-
Rethinking trials: the pros and cons of protocol amendments
This view is shared by Chris Learn, who said immunotherapy studies are more prone to amendments than other types of research.
-
A snapshot of Crescendo Biologics
Our T-cell-enhancing molecules are designed to boost the body’s natural immune system to either further improve patient outcomes – in those cancers where existing immunotherapies are already having some
-
European biotech: a new generation of leaders emerges
This means its clinical outcomes could match those seen in the CAR-Ts, but without the complexity and cost of delivering these immunotherapies, and without their difficult-to-manage side effects.
More from intelligence
Approximately 5 fully matching, plus 53 partially matching documents found.
Latest appointments
-
New hires at Crescendo, Healx and Galecto
He joins Galecto from eTheRNA immunotherapies, a Belgian mRNA immunotherapy company.
-
New hires at bluebird bio, BioNTech and Provention Bio
In his role as CCO at Provention, Hoitt will be responsible for the development and execution of the company’s global commercial strategy for its type 1 diabetes prevention immunotherapy
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Immunotherapy-focused UK biotech company Immunocore has unveiled Bahija Jallal as its new chief executive and director of the board.
-
BMS appoints new commercial leader, Davies joins Eisai and more
The company has identified the novel biomarker of tumour mutation burden as a key plank of its growth strategy for the immunotherapy. ... Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as
-
Industry appointments
Zelluna Immunotherapy appoints CSO. Norwegian biotech Zelluna Immunotherapy has named Namir Hassan as its chief scientific officer (CSO). ... antigen. Hassan’s new role, however, will see him manage and plan the next stages of development for the TCR
More from appointments
Approximately 2 fully matching, plus 45 partially matching documents found.
Latest from PMHub
-
Precision paediatrics: Treating patients with CAR-T
SA: CAR-T cell therapy is an innovative immunotherapy that modifies the body’s own immune T-cells to start attacking cancer cells. ... Immunotherapy has been around for many years, but this is the first time that the patients’ own T-cells have been
-
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. ... OncoSec's lead immunotherapy platform – TAVO (tavokinogene
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
There is a strong unmet medical need for novel immunotherapy approaches such as TAVO. ... Presented at: Society for Immunotherapy of Cancer 33rd Annual Meeting; November 7–11, 2018; Washington, DC.
-
Lucid Group welcomes new magical talent and boosts their medical writing teams with hires in the US and UK
With three years’ healthcare communications experience, and a wealth of knowledge in epilepsy, immunotherapy and oncology Andrew comments, “I have had a very fulfilling first two months at Lucid; the team
-
SWITCHED ONcology Patient Experience Focus Group Full Discussion
The focus group provided deeper insight in to a number of themes including the transformation of cancer understanding, the barriers to cancer diagnosis, the advent of new treatments including immunotherapy, communication
More from PMHub
Approximately 11 fully matching, plus 15 partially matching documents found.
Featured jobs
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
- Senior Medical Writer, MedComms Agency
-
Salary TBC
-
Publications director
-
Competitive salary and bonus scheme
-
Account Director
-
£Competitive Salary
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Account director
-
Competitive salary and bonus scheme
-
Account Manager
-
£Competitive Salary
- Account Director, Healthcare Communications
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
- Digital Associate Director - Medcomms
-
£65000 - £80000 per annum
-
Senior External Communications Lead
-
£Competitive Salary
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
-
Scientific Director
-
£60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more
-
Experienced medical editor
-
Competitive salary and bonus scheme
-
Account Manager (PR)
-
Great Benefits
- Group Director of Medical Affairs and Scientific Strategy, Medic...
-
Substantial six figure package
Subscribe to our email news alerts
- Novo Nordisk awakens its ‘Sleeping Beauty’
- Merck KGaA divests allergy business to Dermapharm
- US backs Sanofi’s ‘fast-track’ coronavirus vaccine
- Genital herpes vaccine candidate heads for human studies
- Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD
- Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD
- Introducing Nucleus POLAR™, a state-of-the-art external expert search engine and engagement management tool
- GSK pays $50m upfront to tap Immatics’ cell therapy platform
- Researchers discover new antibiotic using AI
- Bedrock Group celebrates a trio of new hires
- Tocagen merges with Forte Biosciences after brain cancer fail
- Immutep spikes on trial of its LAG-3 drug with Keytruda
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- Novo Nordisk awakens its ‘Sleeping Beauty’
- Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
- How will the Tories’ historic win shape the NHS?
- Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
- CSR 'Christmas Spirit' 2019
- OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...
Quick links
Infographics
